Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)

Calvo Martínez, Lourdes; García Mata, Jesús; López López, Rafael; Castellanos Diez, Javier
Thumbnail
Estatísticas
Estatísticas
Identificadores
Identificadores
Rexistro completo
Servizos
Servizos
RISMendeleyLinksolver
Data de publicación
2011
Título da revista
CANCER RESEARCH
Tipo de contido
Publicación de congreso